Lipocine Inc.
LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates aā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.53
Price+0.13%
$0.01
1Y
Price
Market Cap
$40.384m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2919.5%
EBITDA Margin-2781.6%
Net Profit Margin-2606.0%
Free Cash Flow Margin-2919.5%
EBITDA Margin-2781.6%
Net Profit Margin-2606.0%
Free Cash Flow MarginRevenue
$4.323m
-61.4%
1y CAGR-79.6%
3y CAGR-83.9%
5y CAGREarnings
-$5.475m
-65671.7%
1y CAGR-21874.6%
3y CAGR-16804.9%
5y CAGREPS
-$1.03
-
1y CAGR+15.6%
3y CAGR-390.4%
5y CAGRBook Value
$14.142m
$16.073m
Assets$1.931m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$5.149m
-292.7%
1y CAGR-67.3%
3y CAGR-93.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company